214 related articles for article (PubMed ID: 14695854)
1. Insights from the gene expression profiling of multiple myeloma.
Claudio JO; Masih-Khan E; Stewart AK
Curr Hematol Rep; 2004 Jan; 3(1):67-73. PubMed ID: 14695854
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling and multiple myeloma.
Shaughnessy J; Zhan F; Barlogie B; Stewart AK
Best Pract Res Clin Haematol; 2005; 18(4):537-52. PubMed ID: 16026736
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
Stewart AK; Fonseca R
J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017
[TBL] [Abstract][Full Text] [Related]
4. SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis.
Felix RS; Colleoni GW; Caballero OL; Yamamoto M; Almeida MS; Andrade VC; Chauffaille Mde L; Silva WA; Begnami MD; Soares FA; Simpson AJ; Zago MA; Vettore AL
Cancer Lett; 2009 Jun; 278(1):41-8. PubMed ID: 19171422
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling defines a high-risk entity of multiple myeloma.
Zhan FH; Barlogie B; John D S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 32(2):191-203. PubMed ID: 17478923
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions.
Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
Acta Haematol; 2014; 132(2):129-33. PubMed ID: 24556596
[No Abstract] [Full Text] [Related]
7. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations.
Agnelli L; Storti P; Todoerti K; Sammarelli G; Dalla Palma B; Bolzoni M; Rocci A; Piazza F; Semenzato G; Palumbo A; Neri A; Giuliani N
Am J Hematol; 2011 Dec; 86(12):E64-6. PubMed ID: 21953534
[TBL] [Abstract][Full Text] [Related]
9. Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma.
Largo C; Alvarez S; Saez B; Blesa D; Martin-Subero JI; González-García I; Brieva JA; Dopazo J; Siebert R; Calasanz MJ; Cigudosa JC
Haematologica; 2006 Feb; 91(2):184-91. PubMed ID: 16461302
[TBL] [Abstract][Full Text] [Related]
10. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.
Bataille R; Robillard N; Avet-Loiseau H; Harousseau JL; Moreau P
Haematologica; 2005 May; 90(5):706-7. PubMed ID: 15921396
[TBL] [Abstract][Full Text] [Related]
11. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
Agnelli L; Bicciato S; Mattioli M; Fabris S; Intini D; Verdelli D; Baldini L; Morabito F; Callea V; Lombardi L; Neri A
J Clin Oncol; 2005 Oct; 23(29):7296-306. PubMed ID: 16129847
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
Mattioli M; Agnelli L; Fabris S; Baldini L; Morabito F; Bicciato S; Verdelli D; Intini D; Nobili L; Cro L; Pruneri G; Callea V; Stelitano C; Maiolo AT; Lombardi L; Neri A
Oncogene; 2005 Apr; 24(15):2461-73. PubMed ID: 15735737
[TBL] [Abstract][Full Text] [Related]
13. Using genomics to identify high-risk myeloma after autologous stem cell transplantation.
Shaughnessy JD; Barlogie B
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):77-80. PubMed ID: 16399589
[TBL] [Abstract][Full Text] [Related]
14. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?
Tassone P; Tagliaferri P; Rossi M; Gaspari M; Terracciano R; Venuta S
Eur J Cancer; 2006 Jul; 42(11):1530-8. PubMed ID: 16820292
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of human cancers.
Bucca G; Carruba G; Saetta A; Muti P; Castagnetta L; Smith CP
Ann N Y Acad Sci; 2004 Dec; 1028():28-37. PubMed ID: 15650229
[TBL] [Abstract][Full Text] [Related]
16. Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines.
Verdelli D; Mattioli M; Fabris S; Nobili L; Intini D; Guerneri S; Todoerti K; Zanella A; Deliliers GL; Lombardi L; Neri A
Haematologica; 2005 Nov; 90(11):1541-8. PubMed ID: 16266902
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling in acute myeloid leukemia.
Bullinger L; Valk PJ
J Clin Oncol; 2005 Sep; 23(26):6296-305. PubMed ID: 16155012
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of interleukin-6 gene expression in the bone marrow of patients with multiple myeloma.
Iwasaki T; Hamano T; Ogata A; Kakishita E
Int J Hematol; 1999 Oct; 70(3):163-8. PubMed ID: 10561908
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
